VUKOTIC, Ranka
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.301
AS - Asia 2.168
EU - Europa 1.695
SA - Sud America 266
Continente sconosciuto - Info sul continente non disponibili 72
AF - Africa 67
OC - Oceania 5
Totale 8.574
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.196
SG - Singapore 656
CN - Cina 464
PL - Polonia 324
HK - Hong Kong 307
GB - Regno Unito 295
VN - Vietnam 284
IT - Italia 247
SE - Svezia 195
BR - Brasile 189
FI - Finlandia 174
BD - Bangladesh 151
DE - Germania 102
RU - Federazione Russa 102
KR - Corea 64
CA - Canada 57
IN - India 43
BG - Bulgaria 39
UA - Ucraina 34
ES - Italia 31
FR - Francia 30
TR - Turchia 30
JP - Giappone 28
AR - Argentina 26
ID - Indonesia 26
NL - Olanda 25
ZA - Sudafrica 24
AE - Emirati Arabi Uniti 21
IQ - Iraq 18
MX - Messico 17
CZ - Repubblica Ceca 15
AT - Austria 13
CO - Colombia 12
VE - Venezuela 12
LT - Lituania 11
MA - Marocco 10
RO - Romania 10
PH - Filippine 9
CL - Cile 8
EG - Egitto 8
MY - Malesia 8
PK - Pakistan 8
CR - Costa Rica 7
DZ - Algeria 7
ET - Etiopia 7
PE - Perù 7
DO - Repubblica Dominicana 6
SA - Arabia Saudita 6
AL - Albania 5
AU - Australia 5
BE - Belgio 5
CH - Svizzera 5
GR - Grecia 5
IE - Irlanda 5
IL - Israele 5
PY - Paraguay 5
TN - Tunisia 5
UZ - Uzbekistan 5
GT - Guatemala 4
JO - Giordania 4
PR - Porto Rico 4
QA - Qatar 4
A2 - ???statistics.table.value.countryCode.A2??? 3
EE - Estonia 3
GE - Georgia 3
JM - Giamaica 3
KH - Cambogia 3
KZ - Kazakistan 3
NP - Nepal 3
RS - Serbia 3
TH - Thailandia 3
UY - Uruguay 3
BO - Bolivia 2
EC - Ecuador 2
HN - Honduras 2
HR - Croazia 2
IR - Iran 2
MT - Malta 2
NI - Nicaragua 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TW - Taiwan 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
GD - Grenada 1
HU - Ungheria 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
Totale 8.498
Salva come PNG Salva come JPEG
Città #
Santa Clara 555
Ashburn 485
Singapore 440
Warsaw 319
Fairfield 313
Hong Kong 303
Chandler 302
Helsinki 168
Nyköping 157
Houston 156
San Jose 146
Woodbridge 124
Wilmington 112
Cambridge 108
Beijing 105
Southend 104
London 100
Los Angeles 100
Seattle 98
Ho Chi Minh City 89
New York 86
Chicago 85
Council Bluffs 75
Hanoi 74
Seoul 55
The Dalles 54
San Diego 52
Hefei 51
Ann Arbor 49
Moscow 46
Dearborn 44
Salt Lake City 44
Princeton 41
Sofia 38
Orem 36
Buffalo 32
Jacksonville 32
Milan 30
Modena 30
Shanghai 30
São Paulo 26
Tokyo 24
Dallas 21
Da Nang 20
Frankfurt am Main 20
Jakarta 20
Palma 18
Boardman 17
Jersey City 17
Haiphong 16
Redwood City 16
Tampa 14
Izmir 13
Vancouver 13
Brno 12
Brooklyn 12
Toronto 12
Elk Grove Village 11
Johannesburg 11
Wuhan 11
Baghdad 10
Belo Horizonte 10
Bremen 10
Denver 10
Guangzhou 10
Nanjing 10
North Bergen 10
Phoenix 10
Reading 10
Redondo Beach 10
Sterling 10
Berlin 9
Bologna 9
Chennai 9
Falls Church 9
Grafing 9
Kilburn 9
Montreal 9
Augusta 8
Cairo 8
Charlotte 8
Chiswick 8
Eugene 8
Istanbul 8
Miano 8
Rome 8
San Francisco 8
Vienna 8
Addis Ababa 7
Amsterdam 7
Columbus 7
Groningen 7
Lauterbourg 7
Newark 7
Poplar 7
Riverside 7
Secaucus 7
Stanford 7
Brasília 6
Campinas 6
Totale 5.927
Salva come PNG Salva come JPEG
Nome #
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 633
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis 429
ANTICOAGULANT THERAPY IS SAFE AND EFFECTIVE IN PREVENTING PORTAL VEIN THROMBOSIS (PVT) IN ADVANCED CIRRHOTIC PATIENTS: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 394
Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C 381
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 326
ENOXAPARIN PREVENTS PORTAL VEIN THROMBOSIS (PVT) AND DECOMPENSATION IN ADVANCED CIRRHOTIC PATIENTS: FINAL REPORT OF A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 314
Reproductive status is associated with the severity of fibrosis in women with hepatitis C. 297
Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study 291
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 249
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 219
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 213
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 209
Clinical and serological profile of primary biliary cirrhosis in men 204
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 198
Familial intrahepatic cholestasis: New and wide perspectives 198
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 191
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 184
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 183
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 178
De novo autoimmune hepatitis in liver transplant: State-of-the-art review 178
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B 172
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 170
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B 166
The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series 163
Bone marrow derived stem cells for the treatment of end-stage liver disease 159
Hepatitis C Virus Core Antigen (HCVAg): An affordable assay to monitor the efficacy of treatment in DAAs era 159
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older 157
The increase of Ribavirin dose improves sustained virological response in HCV-Genotype 1 patients with a partial response to PEG-Interferon and Ribavirin. 150
Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group 150
Hepatitis B virus and immune response 144
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation 142
Insights into cancer severity from biomolecular interaction mechanisms 142
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study 139
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort 137
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 131
Impact of psychosocial status on liver transplant process 130
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 129
Hepatitis C virus eradication in the elderly: The challenge worth a long-life elixir? 122
Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholi fatty liver disease: an Italian community-based population study 121
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 116
Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options 115
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma 91
Totale 8.574
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.095
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.095
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022668 0 30 40 40 16 51 23 87 83 77 123 98
2022/2023746 108 105 69 78 74 114 11 67 81 4 21 14
2023/2024455 21 25 27 70 102 21 43 47 5 6 21 67
2024/20251.530 47 12 4 121 353 241 67 121 171 102 118 173
2025/20263.704 188 63 165 322 535 547 406 191 389 376 319 203
2026/2027203 160 43 0 0 0 0 0 0 0 0 0 0
Totale 8.574